Dr. Matthew J. Frigault (Harvard Medical School, Massachusetts General Hospital—Boston, MA) discusses the Phase 1 Study of CAR T-ddBCMA in relapsed/refractory myeloma patients. #asco2022
What is the purpose of this trial?
Chimeric Antigen Receptor (CAR) T cell therapies targeting B-cell maturation antigen (BCMA) have demonstrated benefit in patients (pts) with relapsed and/or refractory Multiple Myeloma (RRMM). CART-ddBCMA is an autologous anti-BCMA CAR T cell therapy that utilizes a novel, synthetic binding domain, called a D-Domain, instead of a typical scFv binder. The objective of this first-in-human trial is to assess the safety and efficacy of CART-ddBCMA.
Conclusion:
To date, CAR T-ddBCMA administration has demonstrated clinical activity, including 100% overall response rate (ORR) with rates of complete response (CR)/stringent complete response (sCR) and ≥ very good partial response (VGPR) of 67% and 88%, respectively. Durable responses beyond 18 months have been observed, including in patients with extramedullary disease (EMD).
Clinical trial information: NCT04155749
ASCO 2022 Abstract: 8003
Doctor Bio:
Dr. Matthew J. Frigault is an Instructor at Harvard Medical School and Clinical Director of the Cellular Immunotherapy Program, BMT Cellular Therapy at Massachusetts General Hospital in Boston, MA.
_______________
Improving Lives | Finding the Cure
In the United States, an estimated 32,270 new multiple myeloma cases will be diagnosed in 2021. 159,985 new myeloma cases are diagnosed yearly.
Founded in 1990, the International Myeloma Foundation (IMF) is the first and largest organization focusing specifically on multiple myeloma. The IMF’s reach extends to more than 525,000 members in 140 countries worldwide. The IMF is dedicated to improving the quality of lives of myeloma patients while working toward prevention and a cure through our four founding principles: Research, Education, Support, and Advocacy.
Subscribe to our channel: [ Ссылка ]
Visit our website at: [ Ссылка ]
Find us online:
Facebook: @myeloma | [ Ссылка ]
Twitter: @IMFMyeloma | [ Ссылка ]
Instagram: @imfmyeloma | [ Ссылка ]
LinkedIn: [ Ссылка ]
Support the IMF! [ Ссылка ]
Category
Nonprofits & Activism
License
Standard YouTube License
In most cases, captions are autogenerated by YouTube.
